title: [A case of advanced breast cancer with multiple lung and liver metastases successfully treated with multi-disciplinary therapy].
abstract: We report a case of advanced breast cancer with multiple lung and liver metastases (T4bN1M1) achieving a significant improvement of QOL by multi-disciplinary therapy. The patient was a 63-year-old woman with slight jaundice who had ascites and an ulcerative breast lump with multiple lung and liver metastases. A core needle biopsy for breast tumor led to a diagnosis of an invasive ductal carcinoma positive for HER2/neu protein expression. She received 6 cycles of tri-weekly docetaxel (60 mg/m2) and weekly trastuzumab. Although the ascites and the jaundice disappeared after chemotherapy, the response for breast tumor, metastatic sites in the lung and the liver were less satisfactory. Fifteen-months later, she received radiation therapy so that metastasis in the brain was recognized. But she had no neurological symptoms. Multi-disciplinary therapy can improve patient's QOL and the clinical outcomes in Stage IV advanced breast cancer.
authors.affiliation: Division of Breast and Endocrine Surgery, Dept. of Surgery, Nihon University School of Medicine.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sakurai
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Enomoto
authors.forename: Sadao
authors.initials: S
authors.lastname: Amano
authors.forename: Akira
authors.initials: A
authors.lastname: Kitajima
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Suzuki
authors.forename: Sadanori
authors.initials: S
authors.lastname: Matsuo
authors.forename: Akiko
authors.initials: A
authors.lastname: Sakamoto
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Kashio
authors.forename: Mayumi
authors.initials: M
authors.lastname: Tani
authors.forename: Nanao
authors.initials: N
authors.lastname: Negishi
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D044584:Carcinoma, Ductal / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D008175:Lung Neoplasms / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D000068878:Trastuzumab